3 results
Approved WMOCompleted
The objectives of this study are to assess the efficacy, safety, and tolerability of a once daily oral dose of laquinimod (0.6 or 1.5 mg) compared to placebo in PPMS patients.
Approved WMORecruiting
To evaluate the efficacy of PTC857 in reducing disease progression in subjects with amyotrophic lateral sclerosis (ALS)
Approved WMORecruiting
To assess benefits and harms of goal directed fluid removal with furosemide versus placebo on patient-important outcome measures in adult ICU patients with fluid overload.